600267.SH
海正药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.06
−7.80%Year over year
Reported trailing growth
- Revenue
- +0.6%
- EBITDA
- —
- EBIT
- +57.4%
- EPS
- +29.3%
- Free cash flow
- -6.1%
- Operating cash flow
- +4.1%
Forward estimates
Based on analyst estimates
- Revenue
- -20.7%
- EBITDA
- -10.2%
- EPS
- -21.2%
Three-year CAGR
- Revenue
- -2.5%
- EBITDA
- +2.1%
- EBIT
- +8.3%
- Net income
- +3.4%
- EPS
- -11.5%
- Free cash flow
- +0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026